Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Aphria

News broke late Tuesday that Canadian cannabis growers Aphria and Tilray are in merger talks and the companies confirmed the merger Wednesday morning.

Aphria-Tilray Marriage Could Mean 420 In December For This Cannabis ETF

LEAMINGTON, Ontario & NANAIMO, British Columbia--(BUSINESS WIRE)--Aphria Inc. and Tilray, Inc. announce definitive agreement to combine and create the world's largest global cannabis company

Aphria and Tilray Combine to Create Largest Global Cannabis Company With Pro Forma Revenue of C$874 Million (US$685 Million)

A deal could be reached and announced within days.

Report: Tilray and Aphria in "Advanced" Merger Talks; Announcement Could Come This Week

Shares in Canadian cannabis companies Aphria Inc. and Tilray Inc. skyrocketed in late trading Tuesday after a report that the companies are in advanced talks to merge.

Cannabis Watch: Aphria, Tilray stocks jump after report that cannabis companies are discussing merger

Aphria Inc. and Tilray Inc. are contemplating a merger

Aphria, Tilray In Talks To Merge: Report

Tilray doesn't have any screaming negatives. But it also lacks the positives needed to catalyze a further rally, or make Tilray stock a compelling buy.

Tilray Stock Still Isn't Quite Good Enough

Tilray stock is back down after its election rally and should remain repressed amid its weakening domestic sales and liquidity. The post Tilray Is Not Your Best Bet at the Growing Cannabis Market appeared first on InvestorPlace.

Tilray Is Not Your Best Bet at the Growing Cannabis Market

Tilray faces mounting pressure to expand globally and its latest hiccup hardly instills any confidence that it may grow the business. The post There Still May Be Time to Sell Tilray Stock Before Everyone Else Does appeared first on InvestorPlace.

There Still May Be Time to Sell Tilray Stock Before Everyone Else Does

Yet, the potential for a short squeeze doesn't make the bull case for Tilray stock. With better pot plays (like Canopy) out there, it's best to avoid this "also ran" pot stock.

Legalization May Be Years Away, So Steer Clear of Tilray

It's fine to anticipate positive developments in the broader cannabis market, but loading up on Tilray stock isn't the best move now. The post Avoid Tilray Stock While Shares Are Fueled by Political FOMO appeared first on InvestorPlace.

Avoid Tilray Stock While Shares Are Fueled by Political FOMO

Pot stocks are continuing to march higher in the wake of the election. Thus, bank on a bottom for Tilray stock using this options trade.

How to Bet the Bottom Is In for Tilray Stock

Aurora Cannabis

Canopy Growth

HEXO Corp

SNDL Inc.

You could rightly say that money managers chased after the green in the third quarter.

The Industry Billionaires Bought Hand Over Fist in Q3

Tilray stock may keep rising with higher cannabis sales and the prospect of profits. Tilray could rise at least another 50% if it becomes profitable on an adjusted EBITDA basis in Q4.

Tilray Could Rise Another 50% Once It Reaches Profits By Q4

Cronos Group

It was a great month for pot stocks, but these massive moves seem like ill-informed speculation to me.

Why Hexo, Cronos Group, and Tilray Surged as Much as 76.5% in November

Cannabis stocks like CGC, TLRY and ACB stock are all on the move Friday after lawmakers voted on a landmark bill. The post Cannabis Stocks: Why CGC, TLRY and ACB Stock Are Moving Today appeared first on InvestorPlace.

Cannabis Stocks: Why CGC, TLRY and ACB Stock Are Moving Today

Arena Pharmaceuticals

GW Pharmaceuticals

OrganiGram Holdings Inc.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcoming week.

This Week in Cannabis: 6 Stocks Pivoting for Serious Growth

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Schultze Special Purpose Acquisition Corp II

Trulieve Cannabis Corp.

The improving regulatory landscape for marijuana stocks could usher in a boom, particularly for companies focused on the U.S. market. The post 7 Marijuana Stocks Hoping 2021 Brings Federal Legalization appeared first on InvestorPlace.

7 Marijuana Stocks Hoping 2021 Brings Federal Legalization

U.S. legalization euphoria has investors chasing a number of terrible cannabis stocks.

3 Pot Stocks to Avoid Like the Plague in December

Marijuana stocks popped on Wednesday after a United Nations commission voted to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a list that includes heroin and fentanyl.

Pot Stocks Get a Lift After a Symbolic Win From the UN

BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021. Hormosan is primarily focused on pain therapy and neurology and is part of the Lupin Group, an international entity that sells innovative drugs and generics. Ho

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?

This stock is prone to leaving investors in the red and unhappy.

1 Risky Cannabis Stock to Avoid

Fastly

Moderna

These stocks could make investors rich next month.

3 Top Breakout Stocks to Watch in December

Amplify Alternative Harvest ETF

Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.

Cannabis Watch: Pot stocks pop ahead of U.S., UN votes on cannabis legalization

As marijuana stocks go, OrganiGram Holdings Inc. (NASDAQ: OGI) is a relatively small player.

News for Tilray Brands Stock (TLRY)